RESEARCH NOTE:
ADVANCED CELL TECH (ACTC)
Last Updated: April 8, 2008 - 11:19am EST
New York -- New York based Ludlow
BioVentures Inc has initiated research coverage on Advanced Cell
Technologies (OTC:ACTC) with a B+ rating, and added to client
speculative watch list.
SUMMARY
Since the first isolation of
hESCs, scientists and industry alike have been working to harness the
power of these cells for the purpose of restoring and regenerating
body systems that have been damaged by disease or injury. Human Embryonic
Stem Cells are those cells which begin to differentiate into neural
cells, muscle cells, cardiac cells, etc upon fertilization of an
embryo. HESC's can be equated to a "blank
slate" ready to be programmed by various genetic codes
in DNA to create various tissues, organs, or bones.
One of the hurdles has been a
commercially viable means for the expansion of sufficient numbers of
the cell types needed for tissue regeneration. With the publication of
work entitled "The ACTCellerate Initiative: large-scale
combinatorial cloning of novel human embryonic stem cell
derivatives," ACT scientists have solved some of these problems.
The paper describes a system that was established to isolate and
clonally expand tissue specific precursors that heretofore could only
be isolated from aborted human fetal tissue.
This research indicates a significant
step forward in the field of embryonics, cellular mapping
and characterization of the cells of early human
development. The ACTCellerate technology could
potentially hasten the translation of human embryonic stem
cell-based therapies into safe and effective products for routine
clinical practice.
Ludlow BioVentures, Inc has initiated research coverage on ACTC with a
B+ rating, and has added the stock to its clients 'speculative' watch
list.
Register here to receive
updates on this research coverage, and on our upcoming NYC biotech
investor conferences.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a
biotechnology company applying cellular technology in the emerging
field of regenerative medicine. The company operates facilities in
California and Massachusetts.
About Ludlow
BioVentures, Inc
|
Based in New York City,
Ludlow BioVenture is a venture capital and research advisory
firm with a specific focus on the renewable and alternative
energy markets. The goal of the firm is to promote investments
into alternative and renewable energy projects and ventures
worldwide. Ludlow BioVentures owns and operates the Ludlow
BioVenture Index, which tracks a wide basket of US traded large
and small cap biotechnology stocks. www.ludlowcapital.com
--------
Contact:
Ludlow BioVentures, Inc.
Thomas J. Latino JD, PhD
Phone: (201)-245-4278
Email: tlatino@ludlowcapital.com
Disclosure: This is NOT a solicitation to Buy or Sell any
security, but rather is for research purposes only. Content
contained herein includes facts, views, opinions and
recommendations of individuals and organizations deemed of
interest. Ludlow BioVentures does not guarantee the accuracy,
completeness or timeliness of, or otherwise endorse these views,
opinions or recommendations, or give investment advice. Ludlow
BioVentures, its affiliates, or directors, may or may not hold a
position in the above security from time to time, and investors
are encourage to consider this as a possible conflict of
interest when reviewing this information. In Compliance with SEC
Rule 17B Ludlow BioVentures was NOT compensated for the
distribution of this research material, but may hold a position
in the above securities in the Ludlow BioTech fund, and should
thus be considered a possible conflict of interest when
reviewing this report and information.
|
|
